The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2019 Lung Cancer and Head & Neck Cancer Symposium
08:12

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Understanding the Distinction of HPV-Mediated (p16+) Oropharynx Cancer from Overall Head&Neck Cancers

FEATURING Gregory Gan
  • 84 views
  • November 12, 2019
12:23

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

De-Escalation of HPV-Mediated (p16+) Oropharynx Cancer Treatment: Rationale for Altered and Radiotherapy, and Surgery Followed by Radiation De-Escalation

FEATURING Gregory Gan
  • 16 views
  • November 12, 2019
10:27

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

De-Escalation of HPV-Mediated (p16+) Oropharynx Cancer Treatment: TORS vs. Definitive (Chemo)Radiotherapy / Future Directions - Proton Therapy

FEATURING Gregory Gan
  • 195 views
  • November 12, 2019
19:34

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Evaluation and Managing Options of the Adult Neck Mass in the Era of Human Papilloma Virus

FEATURING Andres M. Bur
  • 267 views
  • November 12, 2019
  • 2
06:51

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on the HPV+ Oropharynx Carcinoma: Cisplatin and Concurrent Radiation Therapy Remain Standard of Care for Non-Smokers Eligible for Cisplatin Chemotherapy

FEATURING Prakash Neupane
  • 32 views
  • November 12, 2019
06:20

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Locally Advanced Nasopharyngeal Cancer: Induction Chemo + Concurrent Chemoradiation Therapy Established Is Current Standard of Care

FEATURING Prakash Neupane
  • 39 views
  • November 12, 2019
08:21

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Recurrent/Metastatic Head&Neck Squamous Cell Carcinoma: 1st Line Pembro for PDL1 CPS>1%, or Carbo+5FU+Pembro for All Is the New Standard of Care

FEATURING Prakash Neupane
  • 562 views
  • November 12, 2019
12:55

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Salivary Gland Carcinoma: Anti-HER2 w/o or w/Chemo Docetaxel Is Highly Active for Salivary Duct, Levatinib As Palliative for Recurrent/Metastatic Adenoid Cystic Carcinoma

FEATURING Prakash Neupane
  • 29 views
  • November 12, 2019
17:19

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti-PD-L1 Agents and Their Combinations, and Outcomes of Pivotal Trials

FEATURING Don Gibbons
  • 838 views
  • November 12, 2019
  • 1
10:16

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Immunotherapy in Advanced NSCLC: Difficulties With Biomarkers Development and Selection

FEATURING Don Gibbons
  • 82 views
  • November 12, 2019
13:33

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Checkpoint Inhibitors in Stage III NSCLC (Pacific Trial Regimen) / Biomarker Development and the Immune Landscape of Early Stage NSCLC

FEATURING Don Gibbons
  • 121 views
  • November 12, 2019
17:11

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Microbiome as a Predictive Ecosystem for Immunotherapy in NSCLC Can Potentially Predict Both Treatment Response and Adverse Effects

FEATURING Jun Zhang
  • 29 views
  • November 12, 2019
12:42

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New KRAS G12C / MET Exon 14 TKI’s for Advanced NSCLC: Favorable Safety Profile and Promising Antitumor Activity of AMG 510 / Capmatinib and Bozitinib

FEATURING Chao Huang
  • 422 views
  • November 12, 2019
22:41

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New TKI’s in Development for Lung Cancer. An Overview of New ROS1 / TRK / ALK / RET / EGFR Inhibitors, Clinical Trial Outcomes, Mechanisms of Resistance, and Safety Profiles

FEATURING Chao Huang
  • 332 views
  • November 12, 2019
  • 1